Review Article
Open Access
CrossMark

The art of healthy longevity 7.0: a nanoimmunoherbogenomic framework for personalized beauty, vitality, and precision Geromedicine

Abstract

Anti-aging medicine is moving away from a product-centered and appearance-reductionist model toward a preventive, functional, and biology-centered science of healthy longevity. Contemporary geroscience conceptualizes aging as a modifiable network of molecular, cellular, immune, metabolic, microbial, epigenetic, and exposomic processes rather than a passive consequence of chronological time. This narrative review substantially expands and integrates the Nanoimmunoherbogenomic framework for personalized beauty, vitality, and precision geromedicine. The framework connects five interdependent domains: nanoscale delivery systems, immune remodeling across the lifespan, standardized herbal bioactives and phytochemicals, genomic and multi-omic stratification, and biomarker-guided precision prevention. Within this model, beauty is not considered merely a visible phenotype, but a systemic readout of mitochondrial performance, immune equilibrium, redox control, dermal repair capacity, gut-skin communication, neuroendocrine stability, circadian coherence, and exposome resilience. Nanoformulation may improve solubility, chemical stability, bioavailability, tissue exposure, controlled release, and route-specific delivery of phytochemicals such as curcumin, quercetin, resveratrol, epigallocatechin gallate, thymoquinone, ginsenosides, gingerols, andrographolide, sulforaphane, berberine, fisetin, luteolin, and apigenin. However, improved delivery should not be equated with proven clinical benefit. The review therefore emphasizes translational discipline, including pharmacokinetic verification, particle characterization, safety assessment, regulatory quality, and clinically meaningful endpoints. To address the need for richer contextualization, this revised paper includes analogous cases from caloric restriction, epigenetic-clock trials, immunosenescence-oriented pilot studies, senolytic translation, lipid-nanoparticle medicine, nano-curcumin clinical trials, personalized nutrition, and skin epigenetic-clock research. Together, these cases demonstrate that the future of healthy longevity should be mechanism-informed, biomarker-conscious, clinically cautious, ethically governed, and personalized without overclaiming. The clinical aim is not the denial of aging, but the extension of healthspan, vitalityspan, skinspan, immune resilience, and meaningful functional life through evidence-informed and individualized interventions.

Keywords: nanoimmunoherbogenomics, healthy longevity, precision geromedicine, inflammaging,immunosenescence, nanophytomedicine, phytochemicals, biological age, epigenetic clocks, skinspan, vitalityspan

Volume 14 Issue 2 - 2026

Dito Anurogo[1,2,3]
[1]Faculty of Medicine and Health Sciences, Universitas Muhammadiyah Makassar, South Sulawesi, Indonesia
[2]Indonesian Molecular Innovation Foundation, Malang Regency, East Java, Indonesia
[3]International Life Institute (ILI), Indonesia

Correspondence: Dito Anurogo, Faculty of Medicine and Health Sciences, Universitas Muhammadiyah Makassar, South Sulawesi, Indonesia

Received: June 9, 2026 | **Published:** June 25, 2026

Abbreviations: AI, artificial intelligence; AMPK, AMP-activated protein kinase; BMI, body mass index; CMC, chemistry, manufacturing, and controls; CRP, C-reactive protein; DNAm, DNA methylation; DQ, dasatinib plus quercetin; EGCG, epigallocatechin gallate; HPA, hypothalamic-pituitary-adrenal; IL, interleukin; LNP, lipid nanoparticle; mTOR, mechanistic target of rapamycin; NF-kB, nuclear factor kappa B; NLR, neutrophil-to-lymphocyte ratio; Nrf2, nuclear factor erythroid 2-related factor 2; RCT, randomized controlled trial; SASP, senescence-associated secretory phenotype; TNF, tumor necrosis factor

Introduction: from cosmetic anti-aging to precision healthy longevity

Anti-aging discourse has historically been dominated by visible appearance, especially wrinkle correction, pigmentation control, skin whitening, facial contouring, and commercial narratives of youthfulness. This formulation is no longer scientifically sufficient. The more relevant biomedical question is how long an individual can preserve cellular integrity, immune competence, metabolic flexibility, tissue repair, cognitive clarity, mobility, social participation, and subjective vitality. The unit of analysis therefore moves from the face alone to the whole organism, and from superficial correction to systemic resilience.[1–4]

Lifespan refers to total years lived. Healthspan refers to the period of life lived with preserved function and without major disability, frailty, or uncontrolled chronic disease. Vitalityspan can be operationally defined as the sustained capacity to move, think, adapt, relate, create, and participate meaningfully. Skinspan, an emerging concept within longevity dermatology, refers to the period during which skin preserves barrier competence, immunological defense, regenerative capacity, sensory function, wound-repair capacity, and aesthetic integrity. These dimensions are biologically interdependent because visible aging, internal aging, and functional aging emerge from overlapping networks of inflammation, mitochondrial function, genomic stability, neuroendocrine regulation, microbial ecology, tissue remodeling, and exposomic burden.[5–8]

The phrase "The Art of Healthy Longevity 7.0" is used here as a translational metaphor for a mature, ethically constrained, and biomarker-informed model of preventive geromedicine. It recognizes that aging is heterogeneous: two individuals of the same chronological age may differ substantially in epigenetic age, immune age, microbiome composition, mitochondrial stress, cardiometabolic vulnerability, sarcopenic risk, neurocognitive resilience, and cutaneous repair capacity. This heterogeneity is the foundation for personalization. Precision geromedicine should therefore identify dominant aging drivers, stratify risk, prioritize modifiable mechanisms, and match interventions to measurable biological need rather than to generic anti-aging promises.[4,9,10]

Review strategy and conceptual scope

This manuscript is a narrative review and conceptual framework rather than a systematic review or meta-analysis. It synthesizes evidence from geroscience, immunology, nanomedicine, phytomedicine, dermatology, systems biology, precision nutrition, biological-age biomarkers, and translational ethics. The objective is not to claim that Nanoimmunoherbogenomics is already a validated clinical discipline, but to define a testable, integrative framework through which healthy longevity interventions can be designed, evaluated, and responsibly communicated.

The review emphasizes three criteria for inclusion of concepts and examples. First, the concept must be mechanistically relevant to aging biology, immune remodeling, skin aging, nutrition, nanodelivery, or multi-omic personalization. Second, the clinical or translational examples must illustrate how a mechanistic intervention can move from hypothesis to biomarker-guided evaluation. Third, the discussion must distinguish plausible biological mechanisms from proven clinical outcomes. This distinction is central because the longevity field is particularly vulnerable to extrapolation from cell culture, animal models, commercial biomarkers, and supplement marketing to unproven claims in healthy humans.[9,11]

Conceptual basis of Nanoimmunoherbogenomics

Nanoimmunoherbogenomics is proposed as an integrative scientific lens linking five domains. The "nano" component refers to nanoscale delivery platforms that may enhance pharmacokinetics, solubility, stability, cellular uptake, controlled release, tissue targeting, route-specific absorption, and theranostic monitoring. The "immuno" component refers to immune remodeling across aging, including immunosenescence, inflammaging, impaired immune surveillance, altered cytokine networks, senescent immune-cell accumulation, trained immunity, hematopoietic skewing, and gut-derived immune dysregulation. The "herbo" component refers to standardized botanical extracts and phytochemicals with antioxidant, anti-inflammatory, senomorphic, senolytic-like, metabolic, epigenetic, or immunomodulatory potential. The "genomic" component extends beyond DNA sequence variation to include nutrigenomics, pharmacogenomics, epigenomics, transcriptomics, proteomics, metabolomics, microbiomics, exposomics, and data-driven biological-age assessment. The combined framework aims to support precision prevention rather than one-size-fits-all supplementation.[9,12–15]

The framework is especially relevant because many phytochemicals have multi-target biology but weak clinical translation. Curcumin, quercetin, resveratrol, EGCG, thymoquinone, sulforaphane, berberine, fisetin, luteolin, apigenin, gingerols, ginsenosides, and andrographolide interact with networks such as NF-kB, Nrf2, AMPK, mTOR, sirtuins, autophagy, mitochondrial quality control, inflammasome activity, redox signaling, endothelial function, and SASP-related mediators.[12,16–18] Yet oral performance may be limited by poor aqueous solubility, chemical instability, intestinal metabolism, first-pass clearance, low tissue penetration, and formulation variability. Nanocarriers may address some of these barriers, but delivery improvement is not synonymous with clinical efficacy. A nano-enabled phytochemical must still demonstrate reproducible identity, exposure, safety, target engagement, biomarker response, and patient-relevant benefit.[19–23]

The most scientifically defensible position is therefore neither rejection nor enthusiasm without evidence. Nanoimmunoherbogenomics should be treated as a translational hypothesis-generation and precision-stratification framework. Its value will depend on whether it improves risk classification, mechanistic targeting, intervention selection, adherence, safety monitoring, and clinically meaningful outcomes compared with standard preventive care (Table 1).

Table 1 Core domains of the Nanoimmunoherbogenomic framework

Domain	Primary scientific function	Representative measures or technologies	Translational caution
Nano	Improve delivery, stability, release kinetics, tissue exposure, and formulation reproducibility.	Liposomes, nanoemulsions, solid lipid nanoparticles, nanostructured lipid carriers, polymeric nanoparticles, phytosomes, micelles, biomimetic vesicles.	Improved bioavailability is not clinical efficacy; particle characterization and safety are mandatory.
Immuno	Identify and modulate inflammaging, immunosenescence, immune exhaustion, and impaired repair.	CRP, IL-6, TNF-alpha, lymphocyte subsets, NLR, vaccine response, immune clocks, microbial translocation markers.	Avoid indiscriminate immune stimulation or suppression; preserve host defense and surveillance.
Herbo	Use standardized multi-target botanical bioactives as candidate modulators of aging pathways.	Curcumin, quercetin, EGCG, resveratrol, thymoquinone, sulforaphane, berberine, fisetin, luteolin, apigenin, gingerols, ginsenosides.	Botanical identity, extraction, dose, contamination, interactions, and pharmacovigilance are critical.
Genomics and multi-omics	Stratify biological heterogeneity and monitor response.	Genomics, epigenetic clocks, transcriptomics, proteomics, metabolomics, microbiomics, digital biomarkers.	Many omics signals remain exploratory; validation, privacy, and interpretability are required.
Precision prevention	Match intervention intensity to dominant aging drivers and patient goals.	Clinical risk assessment, functional tests, body composition, dermatologic grading, lifestyle metrics, follow-up biomarkers.	Precision is not maximal testing; it is better risk-benefit matching.

Citation: Anurogo D. The art of healthy longevity 7.0: a nanoimmunoherbogenomic framework for personalized beauty, vitality, and precision Geromedicine. *MOJ Surg.* 2026;14(2):51–59. DOI: 10.15406/mojs.2026.14.00313

Aging as an interconnected network of hallmarks

The hallmarks-of-aging framework provides a mechanistic map for understanding why biological aging cannot be reduced to a single pathway or a single product. The 2023 update emphasized genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, disabled macroautophagy, deregulated nutrient sensing, mitochondrial dysfunction, cellular senescence, stem-cell exhaustion, altered intercellular communication, chronic inflammation, and dysbiosis.[1] These hallmarks form a reciprocally reinforcing network. Mitochondrial dysfunction can increase reactive oxygen species and inflammatory signaling. Chronic inflammation can amplify cellular senescence, extracellular-matrix remodeling, insulin resistance, endothelial dysfunction, and neurodegenerative risk. Dysbiosis can weaken intestinal barrier integrity and alter immune tone. Epigenetic drift can modify tissue identity and repair competence. Nutrient-sensing dysregulation can alter autophagy, insulin signaling, lipid metabolism, and regenerative capacity.[1,2,4]

This network logic explains why single-target anti-aging claims are often biologically inadequate. A patient with dominant metabolic aging may require glycemic stabilization, resistance training, sleep optimization, visceral-adiposity reduction, and nutrition personalization. A patient with dominant inflammatory aging may require periodontal assessment, microbiome restoration, anti-inflammatory dietary patterning, exercise titration, sleep repair, stress regulation, and evaluation of chronic infection or autoimmune activity. A patient with dominant cutaneous photoaging may require ultraviolet protection, pigment control, barrier restoration, retinoid-based repair, antioxidant strategies, and dermatologic surveillance. The hallmarks therefore do not prescribe identical protocols; they guide individualized assessment, prioritization, and monitoring.[4,7,8,11]

Immunosenescence, inflammaging, and immune resilience

Immunosenescence is not merely immune weakness. It is immune remodeling across innate and adaptive compartments. Characteristic features include thymic involution, reduced naive T-cell output, clonal expansion of memory or exhausted T cells, altered CD4/CD8 balance, impaired B-cell repertoire diversity, reduced vaccine responsiveness, natural killer-cell changes, macrophage and neutrophil dysfunction, increased myeloid bias, and hematopoietic stem-cell skewing. Inflammaging describes chronic, sterile, low-grade inflammation driven by senescent cells, mitochondrial damage-associated molecular patterns, inflammasome activation, adipose inflammation, microbial translocation, oxidative stress, lifelong antigenic stimulation, and impaired resolution biology.[24–26]

The clinical implication is that longevity medicine must incorporate immune phenotyping without reducing it to simplistic immune stimulation. A biologically older immune system may show elevated CRP, IL-6, TNF-alpha, altered NLR, lymphocyte subset imbalance, low-grade endotoxemia, reduced vaccine response, or changes in cytomegalovirus-associated T-cell expansion. However, immune aging is shaped by sex, ancestry, microbiome, infection history, adiposity, nutrition, psychosocial stress, sleep, physical activity, medications, and socioeconomic exposures. The precision task is immune rebalancing: reducing maladaptive chronic inflammation while preserving immune surveillance, antimicrobial defense, tissue repair, and vaccine competence.[24–27]

This distinction matters for herbal and nutraceutical strategies. A compound described as immunomodulatory may be useful in one context and inappropriate in another. For example, an anti-inflammatory compound could be beneficial in a state of sterile chronic inflammation but problematic if it suppresses protective host defense during infection or interferes with immunotherapy. Therefore, Nanoimmunoherbogenomics should integrate immune context, clinical indication, medication use, and monitoring rather than applying identical supplement stacks to all individuals.

Precision geronutrition as molecular medicine

Nutrition is a primary interface between environment and genome. It regulates nutrient-sensing pathways, mitochondrial function, redox balance, gut microbial ecology, immune tone, endocrine signaling, body composition, epigenetic marks, and cardiometabolic risk. In longevity science, nutrition should not be reduced to calories or macronutrient arithmetic alone. Protein quality and timing support muscle protein synthesis, immune competence, collagen turnover, and frailty prevention. Fiber supports short-chain fatty-acid production, intestinal barrier integrity, glycemic control, and anti-inflammatory signaling. Phytonutrients influence xenobiotic defense, Nrf2 activation, NF-kB signaling, mitochondrial stress response, and redox homeostasis. Omega-3 fatty acids participate in membrane physiology and resolution biology. Micronutrients such as vitamin D, zinc, selenium, magnesium, B vitamins, and carotenoids contribute to immune metabolism, DNA repair, antioxidant defense, and neuromuscular function.[28–31]

Precision geronutrition recognizes that dietary response varies according to age, sex, ancestry, genotype, epigenetic state, microbiome composition, insulin sensitivity, renal function, liver function, medication use, physical activity, sleep, inflammatory burden, disease history, and socioeconomic context. The personalized postprandial-glycemic-response study by Zeevi et al. demonstrated that clinical data, dietary habits, anthropometrics, physical activity, and microbiome features can be integrated to predict individualized glucose responses to meals.[32] Although not a longevity trial, it provides an important analogue: "healthy" or "anti-aging" nutrition cannot be fully generalized without considering person-specific biology.

For longevity-oriented practice, the aim is not dietary extremism. Overly aggressive caloric restriction, fasting, or protein restriction may worsen sarcopenia, frailty, bone loss, mood symptoms, or eating-disorder risk in susceptible individuals. The goal is adaptive nutrition that protects muscle, immune resilience, metabolic stability, sleep quality, gut ecology, and long-term adherence. Biomarker-guided nutrition should complement, not replace, careful clinical assessment and functional outcomes.[11,28,29]

Herbal bioactives as multi-target geroprotective candidates

Herbal bioactives are attractive in geroscience because aging is multi-pathway. Curcumin may regulate NF-kB, Nrf2, inflammatory cytokines, oxidative stress, and cellular-senescence-related signaling. EGCG has been studied in relation to redox biology, autophagy, lipid metabolism, and inflammatory signaling. Quercetin is frequently discussed for antioxidant, anti-inflammatory, and senolytic-like properties, especially in combination strategies. Resveratrol interacts with sirtuin-related signaling, AMPK, mitochondrial function, endothelial biology, and neuroinflammation. Thymoquinone,

sulforaphane, berberine, fisetin, luteolin, apigenin, gingerols, ginsenosides, andrographolide, and xanthorrhizol represent additional candidate modulators of oxidative stress, inflammation, xenobiotic defense, nutrient sensing, and senescence-associated pathways.[12,16–18,33]

Despite this promise, phytomedicine in longevity must avoid romantic overgeneralization. Botanical identity, cultivation conditions, extraction method, chemical standardization, dose, formulation, pharmacokinetics, contamination risk, adulteration, herb-drug interaction, hepatic safety, renal safety, anticoagulant effects, endocrine effects, pregnancy status, autoimmune status, cancer history, and concurrent immunotherapy must be considered. A phytochemical that is mechanistically interesting in vitro may fail in humans due to inadequate exposure, rapid metabolism, poor tissue targeting, or toxicity at effective doses. Thus, botanical interventions should be treated as candidate multi-target modulators requiring standardization, pharmacovigilance, biomarker endpoints, randomized trials, and individualized risk assessment.[12,19,20]

The senolytic literature illustrates the danger of oversimplification. The combination of dasatinib plus quercetin has been evaluated in idiopathic pulmonary fibrosis and other senescence-associated contexts, but this does not justify unmonitored quercetin use as a generic longevity intervention. The translational lesson is that phytochemicals may participate in clinically relevant mechanistic strategies, yet they require disease context, dosing rationale, safety monitoring, and carefully chosen endpoints.[34,35]

Nanotechnology for herbal delivery and longevity translation

Nanotechnology addresses one of the major translational barriers in phytomedicine: delivery. Many plant-derived compounds have low water solubility, poor gastrointestinal stability, rapid hepatic metabolism, limited absorption, and insufficient tissue penetration. Nanoformulation can improve dissolution, protect labile compounds from degradation, increase mucosal permeability, prolong circulation, modify biodistribution, enable controlled release, and support co-delivery of synergistic compounds. Liposomes and nanoemulsions may enhance delivery of lipophilic molecules. Solid lipid nanoparticles and nanostructured lipid carriers may support stability and sustained release. Polymeric nanoparticles may enable controlled degradation and ligand conjugation. Phytosomes may improve membrane interaction. Biomimetic and extracellular-vesicle-inspired carriers may improve tissue compatibility, although scalable standardization remains difficult.[19–23]

Healthy longevity applications may include inflammatory, cardiovascular, neurodegenerative, metabolic, dermatologic, musculoskeletal, and immune-aging contexts. Nanoformulated curcumin, resveratrol, quercetin, catechins, and related bioactives have been explored in preclinical and clinical models of oxidative stress, inflammation, sepsis, cancer, cardiovascular injury, and neuroinflammatory disease.[20,22,36–38] For skin health, nanocarriers may improve topical penetration of antioxidants, retinoid-like molecules, peptides, barrier-supportive lipids, DNA-repair enzymes, and microbiome-oriented actives. For brain aging, intranasal nanocarriers are being investigated as a route that may partially bypass blood-brain-barrier limitations, although translational uncertainties remain substantial.[21]

Nanodelivery also introduces new safety and regulatory responsibilities. Particle size distribution, polydispersity, surface charge, morphology, crystallinity, drug loading, release kinetics, protein corona, complement activation, biodegradability, accumulation, genotoxicity, reproductive safety, immunogenicity, manufacturing reproducibility, stability, scalability, and environmental fate should be evaluated before preventive use in healthy populations. The clinical safety threshold for generally healthy individuals is higher than for patients with severe disease. Therefore, nanophytomedicine must be developed through robust chemistry, manufacturing, and controls rather than through the assumption that "natural" and "nano" automatically imply safety.[19,23,39]

Genomics, multi-omics, and biological age as precision tools

Precision geromedicine depends on measuring aging more accurately than chronological age alone. Biological-age biomarkers include DNA-methylation clocks, transcriptomic signatures, proteomic patterns, metabolomic profiles, glycomic markers, immune phenotypes, microbiome clocks, telomere-related measures, clinical chemistry indices, imaging markers, functional tests, and digital biomarkers from wearables. These tools are not interchangeable. Some estimate mortality risk, others estimate organ-specific aging, inflammatory burden, immune remodeling, disease vulnerability, or intervention response. Current expert frameworks emphasize that biomarkers of aging require analytical validity, biological interpretability, longitudinal stability, responsiveness to interventions, and clinical utility before routine clinical decision-making.[9,10,40]

In Nanoimmunoherbogenomics, multi-omics functions as the personalization engine. Genomics may identify inherited susceptibility, pharmacogenomic risk, nutrient-response variability, and disease predisposition. Epigenomics may estimate biological age and capture aspects of cumulative exposures. Transcriptomics may reveal inflammatory, mitochondrial, senescence, or repair signatures. Proteomics may identify circulating mediators of tissue aging. Metabolomics may reveal mitochondrial stress, amino-acid imbalance, lipid dysfunction, oxidative products, bile-acid alterations, or microbial metabolites. Microbiomics may identify dysbiosis, reduced diversity, loss of butyrate-producing organisms, pro-inflammatory taxa, or altered functional pathways. When integrated with clinical and functional data, these signals may support precision prevention.[9,32,40–42]

However, overinterpretation is a major risk. Many commercial omics tests remain exploratory. Epigenetic-clock changes do not automatically prove reduced disease risk, delayed disability, or longer lifespan. Multi-omic algorithms trained in one population may not generalize across ancestry, age, socioeconomic context, or disease status. Clinical decisions should therefore combine molecular data with standard clinical assessment, medication review, functional outcomes, safety, cost, patient goals, and longitudinal monitoring (Table 2).[9–11]

Gut-skin-immune-brain axis: beauty and vitality as systemic readouts

Beauty and vitality are increasingly understood as systemic expressions of internal biological balance. Skin is an immune, endocrine, neural, microbial, vascular, metabolic, and barrier organ. Its aging is shaped by intrinsic programs and extrinsic exposures such as ultraviolet radiation, pollution, smoking, sleep loss, psychological stress, glycemic excess, nutritional inadequacy, alcohol, medication exposure, and chronic inflammation. Skin aging involves collagen fragmentation, elastin disorganization, extracellular-matrix

degradation, melanocyte dysregulation, barrier impairment, sebaceous changes, vascular alteration, mitochondrial dysfunction, senescent-fibroblast accumulation, altered matrix metalloproteinase activity, reduced repair capacity, and immune remodeling.[5–8,43]

Table 2 Beauty and vitality as systemic readouts rather than isolated aesthetic outcomes

Observable dimension	Potential biological drivers	Candidate measurable indicators	Clinical implication
Skin luminosity and texture	Mitochondrial function, redox balance, hydration, barrier integrity, extracellular-matrix turnover.	Transepidermal water loss, hydration measures, photodamage grade, collagen/elastin imaging, oxidative-stress markers.	Topical therapy should be paired with sleep, photoprotection, nutrition, and inflammation control.
Delayed wound healing	Immunosenescence, diabetes risk, malnutrition, vascular dysfunction, steroid exposure, zinc/vitamin D deficiency.	HbA1c, albumin/prealbumin when indicated, CBC, CRP, vascular assessment, medication review.	Aesthetic intervention should be postponed or modified if repair biology is impaired.
Fatigue and low vitality	Sleep disruption, anemia, thyroid disease, inflammation, sarcopenia, depression, mitochondrial stress.	CBC, ferritin, TSH when indicated, CRP, grip strength, gait speed, sleep metrics, body composition.	Vitalityspan requires diagnosis of reversible medical contributors before supplementation.
Accelerated visible aging	UV exposure, pollution, smoking, glycation, stress, circadian disruption, dysbiosis, chronic inflammation.	Exposome history, skin aging grade, glucose/HbA1c, CRP, sleep assessment, lifestyle assessment.	Skinspan is improved by combined dermatologic and systemic prevention.

The gut-skin-immune-brain axis provides a plausible integrative mechanism. Gut dysbiosis can reduce short-chain fatty-acid production, weaken epithelial barrier integrity, increase microbial translocation, and amplify systemic inflammation. These changes can influence skin inflammation, oxidative stress, neuroendocrine signaling, and barrier function. Psychological stress activates HPA-axis pathways and increases cortisol exposure, which may impair wound healing, reduce antioxidant defense, and promote matrix degradation. Sleep disruption alters circadian gene expression, immune function, glycemic control, and skin repair. Physical inactivity worsens insulin resistance, sarcopenia, inflammation, and vascular function. In this model, beauty is not separated from physiology; it becomes a visible phenotype of mitochondrial efficiency, immune equilibrium, microbial diversity, circadian coherence, connective-tissue renewal, and exposome resilience.[6-8,43–45]

Skin-specific epigenetic-clock research provides an important bridge between visible appearance and molecular aging. The development of clocks associated with wrinkle grade, visual facial age, and visual age progression illustrates how aesthetic phenotypes may be connected to measurable biological processes.[46] This does not mean that epigenetic clocks can yet prescribe cosmetic or longevity interventions in routine practice. It means that the next generation of dermatologic longevity research should evaluate interventions using integrated endpoints: visual grading, barrier function, histological markers, molecular age, inflammatory signatures, patient-reported outcomes, and safety.

Personalized clinical framework for healthcare professionals

A responsible clinical framework begins with careful assessment. The clinician should define the patient's goals, distinguish aesthetic desire from functional decline, assess chronic disease risk, review medications and supplements, document sleep, nutrition, exercise, stress, alcohol, smoking, sun exposure, oral health, skin practices, reproductive status, and family history. Baseline measures may include blood pressure, waist circumference, body composition, fasting glucose, HbA1c, lipid profile, renal function, liver enzymes, complete blood count, ferritin, vitamin D when indicated, thyroid function when clinically justified, CRP or other inflammatory markers in selected cases, and functional measures such as grip strength, gait speed, balance, cardiorespiratory fitness, and frailty screening. Dermatologic assessment may include photodamage grading, pigmentation, barrier status, acne or rosacea activity, hair status, wound healing, and skin-cancer risk.[9–11,47]

Intervention should follow prioritization rather than accumulation. Foundational strategies include resistance training, aerobic activity, mobility work, adequate protein, diverse plant-rich nutrition, fiber sufficiency, glycemic stability, healthy fat quality, sleep regularity, circadian alignment, stress regulation, social connection, sun protection, vaccination, oral health, and avoidance of tobacco and ultra-processed excess. Herbal and nutraceutical strategies should be individualized, standardized, interaction-checked, and monitored. Nanoformulated products should not be selected merely because they are "nano"; they should be selected only when formulation quality, safety data, rationale, dose, and monitoring are clear.[11,19,23]

Follow-up should track symptoms, function, adherence, adverse effects, laboratory markers, body composition, dermatologic endpoints, and patient-relevant outcomes. Precision medicine is not more testing for its own sake. It is improved matching between biological need, intervention intensity, safety, and measurable response. The clinical algorithm should therefore move through five stages: define the goal, phenotype the dominant aging drivers, select the least risky evidence-informed intervention, monitor response and safety, and de-intensify or revise when the risk-benefit balance is unfavorable (Table 3).

Similar cases and translational analogues enriching the Nanoimmunoherbogenomic discussion

Several related cases help contextualize the Nanoimmunoherbogenomic proposal and prevent it from remaining an abstract concept. These cases are not presented as direct proof that nanoherbal or multi-omic longevity protocols extend lifespan in healthy adults. Rather, they illustrate how mechanism-informed interventions, biomarker endpoints, precision stratification, and translational governance can move aging science from speculation toward testable clinical models.

Table 3 Practical clinical algorithm for responsible Nanoimmunoherbogenomic care

Step	Question	Core actions	Safety checkpoint
1. Goal definition	Is the goal aesthetic, functional, preventive, or disease-related?	Clarify patient priorities, expectations, symptoms, and time horizon.	Screen for unrealistic expectations, body-image distress, and commercial pressure.
2. Phenotyping	Which aging drivers appear dominant?	Assess metabolic, immune, dermatologic, musculoskeletal, cognitive, sleep, stress, and microbiome-related factors.	Identify red flags requiring standard medical evaluation.
3. Foundational intervention	What low-risk, high-value intervention should come first?	Prioritize exercise, nutrition, sleep, circadian alignment, photoprotection, oral health, vaccination, and tobacco avoidance.	Avoid supplement escalation before foundations are addressed.
4. Targeted adjuncts	Is a herbal, nutraceutical, or nanoformulated adjunct justified?	Use standardized products with rationale, dose, duration, interaction screening, and monitoring plan.	Check liver/renal risk, anticoagulants, pregnancy, autoimmunity, cancer therapy, and polypharmacy.
5. Follow-up	Did the intervention improve function, biomarkers, or skin outcomes safely?	Monitor adherence, adverse effects, lab markers, function, body composition, dermatologic endpoints, and patient-reported outcomes.	Stop or de-intensify if benefit is unclear or harm/cost increases.

The CALERIE trial provides a model for nutritional geroscience because it evaluated long-term caloric restriction in healthy, non-obese adults and later examined DNA-methylation measures of biological aging. The intervention slowed the pace-of-aging measure DunedinPACE, but did not significantly alter several biological-age estimates such as PhenoAge and GrimAge, and the effect sizes were small.[29,48] The lesson for Nanoimmunoherbogenomics is that mechanistic interventions can be tested with aging biomarkers, but biomarker selection and interpretation require caution.

The DO-HEALTH epigenetic-clock analysis provides a second analogue because it evaluated vitamin D, omega-3, and exercise in older adults. The study reported small protective effects of omega-3 across several clocks over three years and an additive effect with vitamin D and exercise for one clock.[30] This case supports a multi-component, low-risk intervention logic, while also emphasizing that modest biomarker effects should not be overinterpreted as proven lifespan extension.

The TRIIM trial provides an immune-aging analogue. It investigated a combination regimen aimed at thymic regeneration and reported reversal of epigenetic aging and immunosenescent trends in a small pilot cohort.[49] Its value for the present framework lies less in immediate clinical adoption than in its structure: immune-aging hypotheses can be tested using imaging, immunophenotyping, metabolic monitoring, and epigenetic biomarkers. The limitation is equally important: small, uncontrolled or pilot studies require replication before routine use.

Senolytic translation using dasatinib plus quercetin in idiopathic pulmonary fibrosis illustrates how a phytochemical can participate in a disease-specific geroscience intervention.[34,35] This case enriches the herbal-bioactive component of Nanoimmunoherbogenomics, but it also warns against consumer simplification. Quercetin in a monitored senolytic trial is not equivalent to unsupervised high-dose quercetin as a wellness product.

Lipid-nanoparticle mRNA vaccines provide a nanomedicine analogue rather than a longevity intervention. Their relevance is translational: clinical success depended on formulation science, particle design, RNA protection, scalable manufacturing, quality control, and regulatory evaluation.[39,50] The lesson for nanophytomedicine is that nanoscale delivery must be treated as a pharmaceutical-technology problem requiring rigorous CMC and safety standards, not merely as a marketing enhancer.

Nano-curcumin and curcumin-nanomicelle trials provide a more direct nanophytomedicine analogue. Clinical studies have investigated nano-curcumin in inflammatory and critical-illness contexts, including sepsis, and meta-analytic work has evaluated curcumin effects on inflammatory biomarkers such as CRP.[36–38] These findings support the plausibility of formulation-enabled phytochemical interventions, but they do not justify generalized claims for healthy longevity without target-population-specific trials.

Finally, personalized nutrition and skin epigenetic-clock studies illustrate how person-specific physiology and visible aging phenotypes can be linked to data-driven prediction. Personalized glycemic-response prediction shows that identical meals can generate different metabolic responses across individuals.[32] Skin epigenetic-clock work suggests that visual aging features can be connected to molecular readouts.[46] Together, these cases support the central thesis: beauty, vitality, metabolism, immunity, microbiome status, and biological age should be interpreted as interacting systems rather than isolated consumer categories (Table 4).

Ethical, regulatory, and translational boundaries

The longevity field is vulnerable to overclaiming because the desire to look younger and live longer is emotionally powerful. Healthcare professionals must distinguish plausible mechanism from proven outcome. A compound may reduce oxidative stress in cell culture without extending human healthspan. A biomarker may shift without demonstrating reduced disease risk. A nanocarrier may improve bioavailability without improving clinical endpoints. An epigenetic clock may move favorably without proving durable functional benefit. A supplement stack may appear sophisticated while increasing hepatotoxic, nephrotoxic, endocrine, anticoagulant, or drug-interaction risk.[9–11]

Ethical longevity care requires transparent communication of uncertainty, avoidance of miracle claims, disclosure of conflicts of interest, respect for patient autonomy, protection from unnecessary cost

or harm, and equitable access. Preventive interventions for generally healthy individuals require a high safety threshold. Nanomaterials and botanical extracts need reproducible manufacturing, contaminant testing, particle characterization, stability testing, dose consistency, pharmacokinetic evaluation, toxicology, and post-market surveillance. Omics-guided personalization requires privacy protection, algorithmic transparency, data security, clinically validated interpretation, and careful attention to ancestry and socioeconomic bias.[9,19,23,40]

Table 4 Similar cases and translational analogues relevant to Nanoimmunoherbogenomics

Case or analogue	Key contribution	Relevance to this framework	Main limitation
CALERIE caloric-restriction analyses	Used DNAm biomarkers to examine whether a lifestyle intervention affects pace of aging [29,48].	Shows how nutrition can be tested as a geroscience intervention with biological-age endpoints.	Effects were modest and clock-dependent; adherence and safety require attention.
DO-HEALTH omega-3, vitamin D, and exercise	Reported small protective effects of omega-3 across DNAm clocks and additive effects for one clock [30].	Supports multi-component precision prevention rather than single-product anti-aging claims.	Biomarker changes do not automatically prove lifespan extension.
TRIIM thymus-regeneration pilot	Explored immunosenescence reversal and epigenetic-age changes [49].	Demonstrates immune-aging trials can integrate imaging, immune profiling, and epigenetic biomarkers.	Small pilot design; replication and safety evaluation are essential.
Dasatinib plus quercetin senolytic studies	Translated senescence biology into early human trials in disease contexts [34,35].	Clarifies how a phytochemical can be part of a monitored geroscience strategy.	Not evidence for unsupervised quercetin wellness use.
LNP mRNA vaccines	Validated clinical translation of nanoscale delivery under rigorous formulation and regulatory standards [39,50].	Provides a benchmark for nanophytomedicine CMC and safety expectations.	Not a longevity intervention; analogy is technological and regulatory.
Nano-curcumin clinical studies	Tested formulation-enabled curcumin in inflammatory and critical-care settings [36-38].	Supports plausibility of nanophytomedicine with immune-inflammatory endpoints.	Disease-specific data cannot be generalized to healthy longevity.
Personalized glycemic-response prediction	Integrated clinical, dietary, activity, and microbiome data to predict individualized meal responses [32].	Supports person-specific precision geronutrition.	Metabolic prediction is not equivalent to longevity outcome validation.
Skin epigenetic-clock studies	Connected visual aging features with molecular age measures [46].	Supports skinspan as a measurable biological domain.	Clinical utility for intervention selection remains under validation.

The language used in healthy longevity should therefore be disciplined. Terms such as "rejuvenation," "biological age reversal," "immune reset," or "nanotherapeutic beauty" should be avoided unless supported by robust evidence. A more responsible vocabulary emphasizes risk reduction, resilience, function, biomarker response, tolerability, and uncertainty. This is not a reduction of innovation; it is the condition for credible innovation.

Future directions: toward Longevity Medicine 7.0

Longevity Medicine 7.0 may emerge from the convergence of geroscience, AI, biomarker science, immunometabolism, microbiome medicine, regenerative dermatology, nanomedicine, precision nutrition, and ethical data governance. AI may integrate clinical records, omics data, imaging, wearable signals, dietary patterns, sleep metrics, microbiome profiles, medication exposures, and environmental data into dynamic risk maps. Epigenetic clocks may be combined with immune clocks, microbiome clocks, proteomic age predictors, glycomic markers, and organ-specific aging signatures. Nanonutraceuticals may be designed for controlled release, target-tissue exposure, immune compatibility, and rational combination delivery. Precision cosmeceuticals may move from surface hydration toward barrier repair, senescence modulation, mitochondrial stress reduction, pigmentation control, inflammatory regulation, and skin microbiome ecology.[9,10,40,46]

The most mature future will not be a marketplace of anti-aging promises. It will be a disciplined ecosystem of preventive geromedicine. In that ecosystem, clinicians identify dominant drivers of biological aging, choose proportionate interventions, monitor response, revise strategy, and protect patients from unsupported claims. The patient is not treated as a passive consumer of products but as an active participant in cellular resilience, functional preservation, and meaningful living.

Priority research questions include: Which biomarker panels best capture nanoherbal target engagement? Which populations benefit most from nanophytochemical delivery? How can pharmacokinetic studies be linked to immune, metabolic, skin, and functional endpoints? What particle characteristics predict benefit versus toxicity? Which combinations of lifestyle, phytochemical, and nanodelivery interventions are synergistic rather than redundant? How can trials avoid excluding older adults with multimorbidity while maintaining safety? How can biological-age tools be validated across ancestry, geography, diet, and socioeconomic context? These questions should shape the next generation of Nanoimmunoherbogenomic research.

Conclusion

Healthy longevity is not the denial of aging. It is the scientific art of aging with preserved function, immune balance, metabolic harmony, mitochondrial competence, microbial diversity, genomic stability, skin resilience, cognitive clarity, mobility, and meaningful participation in life. Nanoimmunoherbogenomics offers a coherent framework for this transition because it connects nanoscale delivery, immune biology, standardized herbal bioactives, genomic intelligence, multi-omic stratification, and precision prevention.

Citation: Anurogo D. The art of healthy longevity 7.0: a nanoimmunoherbogenomic framework for personalized beauty, vitality, and precision Geromedicine. *MOJ Surg.* 2026;14(2):51–59. DOI: 10.15406/mojs.2026.14.00313

The promise of this framework lies in personalization, not exaggeration. Its clinical value will depend on rigorous evidence, careful safety evaluation, validated biomarkers, ethical communication, reproducible formulation science, and integration with foundational lifestyle medicine. Similar cases from caloric restriction, epigenetic-clock trials, immunosenescence studies, senolytics, lipid-nanoparticle translation, nano-curcumin research, personalized nutrition, and skin-aging clocks show that the future of longevity science should be mechanistic, measurable, clinically cautious, and deeply integrative. The most advanced anti-aging paradigm is therefore not the pursuit of looking younger at any cost. It is the pursuit of living longer, healthier, stronger, more beautiful from within, and more meaningful through biologically informed care.

Declarations and submission notes

Funding: none.

Competing interests: none.

Ethics approval and consent to participate: Not applicable for this narrative review.

Data availability: No new empirical dataset was generated in this narrative review.

Author contribution: The manuscript is currently prepared as a single-author narrative review and conceptual framework.

Author's note

At the time this manuscript was prepared, Dito Anurogo was undergoing the process of transferring his institutional homebase affiliation to Universitas Telogorejo Semarang, Central Java, Indonesia.

Acknowledgments

This infographic was originally conceptualized and designed by Dito Anurogo. Generative artificial intelligence was used as an official assistive tool for visual production, while the intellectual concept, scientific structure, and design direction were developed by the author.

Conflicts of interest

The authors declare that there are no conflicts of interest.

References

1. Lopez–Otin C, Blasco MA, Partridge L, et al. Hallmarks of aging: An expanding universe. *Cell.* 2023;186(2):243–278.
2. Lopez–Otin C, Blasco MA, Partridge L, et al. The hallmarks of aging. *Cell.* 2013;153(6):1194–1217.
3. Kennedy BK, Berger SL, Brunet A, et al. Geroscience: Linking aging to chronic disease. *Cell.* 2014;159(4):709–713.
4. Campisi J, Kapahi P, Lithgow GJ, et al. From discoveries in ageing research to therapeutics for healthy ageing. *Nature.* 2019;571(7764):183–192.
5. Krutmann J, Bouloc A, Sore G, et al. The skin aging exposome. *J Dermatol Sci.* 2017;85(3):152–161.
6. Passeron T, Krutmann J, Andersen ML, et al. Clinical and biological impact of the exposome on the skin. *J Eur Acad Dermatol Venereol.* 2020;34(Suppl 4):4–25.
7. DelaO–Escamilla A, Khalil S, Galadari H, et al. Epigenetic clocks in skin aging: From exposome drivers to biomarkers and therapeutic interventions. *Clin Cosmet Investig Dermatol*. 2025;18:3681–3694.
8. Min M, Egli C, Sivamani RK. The gut and skin microbiome and its association with aging clocks. *Int J Mol Sci*. 2024;25(13):7471.
9. Moqri M, Herzog CMS, Poganik JR, et al. Biomarkers of aging for the identification and evaluation of longevity interventions. *Cell.* 2023;186(18):3758–3775.
10. Lyu YX, Fu Q, Wilczok D, et al. Longevity biotechnology: Bridging AI, biomarkers, geroscience and clinical applications for healthy longevity. *Aging (Albany NY)*. 2024;16(20):12955–12976.
11. Barzilai N, Cuervo AM, Austad S. Aging as a biological target for prevention and therapy. JAMA. 2018;320(13):1321–1322.
12. Vaiserman A, Koliada A, Zayachkivska A, et al. Nanodelivery of natural antioxidants: An anti–aging perspective. *Front Bioeng Biotech.* 2020;7:447.
13. Chen R, Mias GI, Li–Pook–Than J, et al. Personal omics profiling reveals dynamic molecular and medical phenotypes. *Cell.* 2012;148(6):1293–1307.
14. Price ND, Magis AT, Earls JC, et al. A wellness study of 108 individuals using personal, dense, dynamic data clouds. *Nat Biotechnol.* 2017;35(8):747–756.
15. Hasin Y, Seldin M, Lusis A. Multi–omics approaches to disease. *Genome Biol.* 2017;18(1):83.
16. Allegra A, Mirabile G, Ettari R, et al. The impact of curcumin on immune response: An immunomodulatory strategy to treat sepsis. *Int J Mol Sci.* 2022;23(23):14710.
17. Gorabi AM, Abbasifard M, Imani D, et al. Effect of curcumin on C–reactive protein as a biomarker of systemic inflammation: An updated meta–analysis of randomized controlled trials. *Phytother Res.* 2022;36(1):85–97.
18. Moussa C, Hebron M, Huang X, et al. Resveratrol regulates neuro–inflammation and induces adaptive immunity in Alzheimer's disease. *J Neuroinflammation*. 2017;14(1):1.
19. Monopoli MP, Aberg C, Salvati A, et al. Biomolecular coronas provide the biological identity of nanosized materials. *Nature Nanotechnol.* 2012;7(12):779–786.
20. Jacob S, Rao R, Gorain B, et al. Solid lipid nanoparticles and nanostructured lipid carriers for anticancer phytochemical delivery: Advances, challenges, and future prospects. *Pharmaceutics.* 2025;17(8):1079.
21. Egba SI, Edeh MO, Uchenna NO, et al. Nasal delivery of phytochemicals using nanocarriers: Therapeutic opportunities and translational challenges. *Int J Nanomedicine*. 2025;20:15017–15041.
22. Unnikrishnan Meenakshi D, Narde GK, Ahuja A, et al. Therapeutic applications of nanoformulated resveratrol and quercetin phytochemicals in colorectal cancer: An updated review. *Pharmaceutics.* 2024;16(6):761.
23. Chavda VP, Nalla LV, Balar P, et al. Advanced phytochemical–based nanocarrier systems for the treatment of breast cancer. *Cancers (Basel)*. 2023;15(4):1023.
24. Franceschi C, Garagnani P, Parini P, et al. Inflammaging: A new immune–metabolic viewpoint for age–related diseases. *Nature Rev Endocrinol.* 2018;14(10):576–590.
25. Santoro A, Bientinesi E, Monti D. Immunosenescence and inflammaging in the aging process: Age–related diseases or longevity? *Ageing Res Rev.* 2021;71:101422.
26. Fulop T, Larbi A, Pawelec G. Human T cell aging and the impact of persistent viral infections. *Front Immunol*. 2013;4:271.
27. Sun C, Li J, Xu H, et al. "Immunopause" no more: Exercise to counter immunosenescence in aging. *Immunity & Ageing.* 2025;22:57.
28. Fontana L, Partridge L. Promoting health and longevity through diet: From model organisms to humans. *Cell.* 2015;161(1):106–118.

29. Waziry R, Ryan CP, Corcoran DL, et al. Effect of long–term caloric restriction on DNA methylation measures of biological aging in healthy adults from the CALERIE trial. *Nature Aging*. 2023;3:248–257.

30. Bischoff–Ferrari HA, Gängler S, Wieczorek M, et al. Individual and additive effects of vitamin D, omega–3 and exercise on DNA methylation clocks of biological aging in older adults from the DO–HEALTH trial. *Nature Aging*. 2025;5:376–385.

31. Ling Z, Liu X, Cheng Y, et al. Gut microbiota and aging. *Crit Rev Food Sci Nutr*. 2022;62(13):3509–3534.

32. Zeevi D, Korem T, Zmora N, et al. Personalized nutrition by prediction of glycemic responses. *Cell.* 2015;163(5):1079–1094.

33. Turner RS, Thomas RG, Craft S, et al. A randomized, double–blind, placebo–controlled trial of resveratrol for Alzheimer disease. *Neurology*. 2015;85(16):1383–1391.

34. Justice JN, Nambiar AM, Tchkonia T, et al. Senolytics in idiopathic pulmonary fibrosis: Results from a first–in–human, open–label, pilot study. *EBioMedicine.* 2019;40:554–563.

35. Nambiar AM, Kellogg DL, Justice JN, et al. Senolytics dasatinib and quercetin in idiopathic pulmonary fibrosis: Results of a phase I, single–blind, single–center, randomized, placebo–controlled pilot trial on feasibility and tolerability. *EBioMedicine.* 2023;90:104481.

36. Karimi A, Pourreza S, Vajdi M, et al. Evaluating the effects of curcumin nanomicelles on clinical outcome and cellular immune responses in critically ill sepsis patients: A randomized double–blind and placebo–controlled trial. *Front Nutr*. 2022;9:1037861.

37. Karimi A, Naeini F, Niazkar HR, et al. Nano–curcumin supplementation in critically ill patients with sepsis: A randomized clinical trial investigating the inflammatory biomarkers, oxidative stress indices, endothelial function, clinical outcomes and nutritional status. *Food & Function*. 2022;13(12):6596–6612.

38. Naghsh N, Kazemi M, Hasani M, et al. Profiling inflammatory biomarkers following curcumin supplementation: An umbrella meta–analysis of randomized clinical trials. *Evid Based Complement Alternat Med*. 2023;2023:4875636.

39. Hou X, Zaks T, Langer R, et al. Lipid nanoparticles for mRNA delivery. *Nature Reviews Materials*. 2021;6:1078–1094.

40. Belsky DW, Caspi A, Corcoran DL, et al. DunedinPACE, a DNA methylation biomarker of the pace of aging. *eLife.* 2022;11:e73420.

41. Biagi E, Franceschi C, Rampelli S, et al. Gut microbiota and extreme longevity. *Current Biol*. 2016;26(11):1480–1485.

42. Rappaport SM, Smith MT. Epidemiology. Environment and disease risks. *Science.* 2010;330(6003):460–461.

43. Rittié L, Fisher GJ. Natural and sun–induced aging of human skin. *Cold Spring Harb Perspect Med.* 2015;5(1):a015370.

44. Cirelli C, Tononi G. The sleeping brain. *Cerebrum.* 2017;2017:cer–07–17.

45. Leproult R, Van Cauter E. Role of sleep and sleep loss in hormonal release and metabolism. *Endocrine Dev.* 2010;17:11–21.

46. Bienkowska A, Raddatz G, Söhle J, et al. Development of an epigenetic clock to predict visual age progression of human skin. *Front Aging.* 2024;4:1258183.

47. Cruz–Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: Revised European consensus on definition and diagnosis. *Age and Ageing.* 2019;48(1):16–31.

48. Das SK, Roberts SB, Bhapkar MV, et al. Body–composition changes in the Comprehensive Assessment of Long–term Effects of Reducing Intake of Energy (CALERIE)–2 study: A 2–y randomized controlled trial of calorie restriction in nonobese humans. *Am J Clin Nutr.* 2017;105(4):913–927.

49. Fahy GM, Brooke RT, Watson JP, et al. Reversal of epigenetic aging and immunosenescent trends in humans. *Aging Cell.* 2019;18(6):e13028.

50. Tenchov R, Bird R, Curtze AE, et al. Lipid nanoparticles: From liposomes to mRNA vaccine delivery, a landscape of research diversity and advancement. *ACS Nano.* 2021;15(11):16982–17015.